Peptidoglycan is predominantly cross-linked by serine DD-transpeptidases in most bacterial species. The enzymes are the essential targets of -lactam antibiotics. However, unrelated cysteine LD-transpeptidases have been recently recognized as a predominant mode of peptidoglycan cross-linking in Mycobacterium tuberculosis and as a bypass mechanism conferring resistance to all -lactams, except carbapenems such as imipenem, in Enterococcus faecium. Investigation of the mechanism of inhibition of this new -lactam target showed that acylation of the E. faecium enzyme (Ldt fm ) by imipenem is irreversible. Using fluorescence kinetics, an original approach was developed to independently determine the catalytic constants for imipenem binding (k 1 ؍ 0.061 M ؊1 min ؊1 ) and acylation (k inact ؍ 4.5 min ؊1 ). The binding step was limiting at the minimal drug concentration required for bacterial growth inhibition. The Michaelis complex was committed to acylation because its dissociation was negligible. The emergence of imipenem resistance involved substitutions in Ldt fm that reduced the rate of formation of the non-covalent complex but only marginally affected the efficiency of the acylation step. The methods described in this study will facilitate development of new carbapenems active on extensively resistant M. tuberculosis.-Lactam antibiotics entered clinical trials in 1941 and have become and remained the most widely used family of drugs for the treatment of severe infections. The success of these molecules as therapeutic agents originates from a combination of properties, including low toxicity, excellent bioavailability, and broad-spectrum bactericidal activity. The latter property is accounted for by the conservation of the target, the active-site serine DD-transpeptidases, thought to catalyze an essential step in cell wall synthesis in all peptidoglycan-containing bacteria (1). The discovery of hundreds of -lactams and of -lactamase inhibitors has made it possible to partially compensate for the erosion of antibacterial activity due to the emergence of various mechanisms of resistance. In Gram-negative bacteria, these mechanisms mostly involve the production of -lactamases, often associated with decreased outer membrane permeability and drug efflux. In Gram-positive bacteria, -lactamase production is also frequent, but modification of the DD-transpeptidases is the clinically relevant mechanism in important pathogens, such as Staphylococcus aureus, Streptococcus pneumoniae, and the enterococci. More recently, bypass of the DD-transpeptidases by a novel class of peptidoglycan polymerases, the LDtranspeptidases, has been shown to convey high level resistance to all -lactams, except the carbapenems, in mutants of Enterococcus faecium selected in vitro (2). Transpeptidases of the DD and LD specificities are structurally unrelated, contain different active-site nucleophiles (Ser versus Cys, respectively), and catalyze formation of different peptidoglycan cross-links (433 versus 333, respectively) (3). The two...